Company Announcement / Press release Archives - Page 15 of 16

Xspray Pharma has carried out a directed share issue raising gross proceeds of approximately SEK 92 million

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Press release Solna, 6 December 2018 Xspray Pharma AB (publ) (“Xspray” or the […]

Xspray Pharma contemplates a directed share issue to continue development of its product portfolio

Additional product patent in the United States for HyNap-Dasa

STOCKHOLM, SWEDEN – December 4, 2018. Xspray Pharma AB (Nasdaq First North: XSPRAY) (“Xspray” or the “Company”) announces that the United States Patent and Trademark Office (USPTO) today has granted a new patent in the United States to Xspray. The new patent, US 10,143,683, covers the pharmaceutical composition of Xspray’s lead product candidate, HyNap-Dasa. This is Xspray’s third product […]

Resolution on long-term incentive programme at extraordinary general meeting in Xspray Pharma on 28 November 2018

Xspray Pharma AB (publ) has today held an extraordinary general meeting where the meeting resolved, in accordance with the Board’s proposal, to adapt a long-term incentive programme (LTI 2018) and to issue a maximum of 234,505 warrants, entailing an increase of the share capital, at full exercise, of maximum SEK 234,505. LTI 2018 includes around 17 […]

Xspray Pharma’s nomination committee for the annual general meeting 2019

STOCKHOLM, SWEDEN – November 23, 2018. Xspray Pharma (Nasdaq First North: XSPRAY) publishes the nomination committee’s composition for the annual general meeting in 2019. The nomination committee, which has been appointed in accordance with the principles adopted by the annual general meeting on 14 May 2018, consists of: Gillis Cullin, appointed by Östersjöstiftelsen Anders Bladh, appointed by Ribbskottet […]

Xspray Pharma prepares for listing on main list

STOCKHOLM, SWEDEN – October 25, 2018. Xspray Pharma (Nasdaq First North: XSPRAY) today announced the decision of the company's board of directors that Xspray will apply for listing of the company's share on Nasdaq Stockholm's main list. The list change is expected to take place within 12 months and is made to improve the prerequisites for a […]

Notice of extraordinary general meeting in Xspray Pharma AB (publ)

The shareholders of Xspray Pharma AB (publ), reg. no. 556649-3671 are hereby summoned to attend the extraordinary general meeting ("EGM") on Wednesday 28 November 2018 at 10.00 a.m. CET at Advokatfirman Cederquist’s premises on Hovslagargatan 3 in Stockholm, Sweden. Right to participate Those who have been recorded as shareholders in the share register kept by […]

Xspray Pharma’s HyNap-Dasa Shows Formal Bioequivalence

STOCKHOLM, SWEDEN – October 10, 2018. Xspray Pharma (Nasdaq First North: XSPRAY) can today present data confirming formal bioequivalence for the company’s lead product candidate, HyNap-Dasa, compared to Sprycel® (dasatinib). ”It has taken us three years of work to come to these encouraging results and the excitement in the company is clearly present today. We […]

Ribbskottet AB increases its stake in Xspray Pharma

STOCKHOLM – September 24, 2018. Xspray Pharma (Nasdaq First North: XSPRAY) (“Xspray”) has received information that Ribbskottet AB has purchased a total of 223,000 shares in the company from Recipharm Venture Fund AB. The transfer took place outside the stock exchange. Ribbskottet’s holding in Xspray now amounts to 10 percent of the number of shares […]

Xspray Pharma announces positive clinical data for its lead product candidate HyNap-Dasa

STOCKHOLM – September 9, 2018. Xspray Pharma AB (Nasdaq First North: XSPRAY) today announces positive data from a clinical bioequivalence study with the company’s lead product candidate HyNap-Dasa. The study results confirmed its primary aim to show bioequivalence of an optimized formulation of HyNap-Dasa compared to Sprycel®. The data will be instrumental in the design […]